The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2023 | STELLAR-303: XL092 with atezolizumab or regorafenib in patients with mCRC
J. Randolph Hecht, MD, University of California, Los Angeles, CA, describes the trial design and rationale of the Phase III STELLAR-303 (NCT05425940) of XL092 with atezolizumab or regorafenib in pre-treated patients with microsatellite stable/microsatellite instability low (MSS/MSI-low) metastatic colorectal cancer, a group of patients with limited treatment options. Previous studies have shown oral tyrosine kinase inhibitors (TKI) such as cabozantinib to have encouraging efficacy, and XL092 is a novel TKI under investigation. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
